Navigation Links
Hospira Receives FDA Approval for Azithromycin for Injection
Date:6/29/2009

LAKE FOREST, Ill., June 29 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for a 500 mg vial of azithromycin for injection in the ADD-Vantage(R) System. The anti-infective medication is a generic version of Pfizer's Zithromax(R) for injection. U.S. sales of generic and name-brand azithromycin for injection were approximately $40 million in 2008.

ADD-Vantage is a specially-designed, two-part system that does not require clinicians to use a needle and syringe to mix the drug and the solution. This reduces the risk of accidental needlesticks, enhances workflow and can result in less waste due to stability and shelf-life factors.

"Hospira is the first company to offer azithromycin in an advanced drug delivery system," said Joshua Gordon, vice president, Specialty Pharmaceuticals, Hospira. "This reinforces Hospira's commitment to healthcare worker safety, as well as to providing safe and effective generic drugs to patients."

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated formats, several of which are proprietary, such as its ADD-Vantage System and iSecure(R) prefilled syringes. Therapeutic areas include anesthesia, anti-infectives, analgesics, cardiovascular, oncology, emergency and other areas. Hospira has approximately 25 generic drugs scheduled to launch in various regions around the world in 2009 and 2010.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira to Host Conference Call for Second-Quarter 2009 Results
2. Hospira Highlights Five Years of Progress and Future Opportunities at Its 2009 Annual Meeting of Shareholders
3. Hospira to Present at Bank of America and Merrill Lynch 2009 Health Care Conference May 13
4. Hospira Launches Biologics Clock and Web Resource to Raise Awareness of Potential Biogenerics Impact
5. Hospira Reports First-Quarter 2009 Results
6. Hospira to Host Conference Call for First-Quarter 2009 Results
7. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
8. Hospira Expands Board of Directors
9. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
10. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
11. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... Washington, DC (PRWEB) , ... May 06, 2016 ... ... Blum, Executive Vice President at CareFirst Blue Cross BlueShield and Former Principal Deputy ... Officer at CareMore - an Anthem Company; Steve Ondra, MD, Chief Medical Officer ...
(Date:5/5/2016)... Seattle, WA (PRWEB) , ... May 05, 2016 ... ... one ranking for overall select performance in the industry’s gold standard KLAS ... Expertise? The Epic Consulting report assessed organizations that specialize in consulting services ...
(Date:5/5/2016)... ... 05, 2016 , ... The U.S. Food and Drug Administration ... to submit their products through an arduous federal approval process. The rules, which ... the market since February 15, 2007. That would essentially ban 99 percent of ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TLC Laser Eye ... Diego, California. The laser eye center will now be called “Gordon Schanzlin New Vision ... staff will remain at the full-service facility to ensure that patients continue to receive ...
(Date:5/5/2016)... Kansas (PRWEB) , ... May 05, 2016 , ... ... that some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian ... of red, green, and brown seaweeds. The pair observed that when photosynthetically active ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocythemia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocythemia Market and ... comprehensive insights into Thrombocythemia pipeline products, ...
(Date:5/4/2016)... Diversified Holdings (NYSE: CODI ) ("CODI," "we," ... market businesses, announced today its consolidated operating results for ... First Quarter 2016 Highlights , Generated Cash Flow ... of $13.6 million for the first quarter of 2016; ... the first quarter of 2016; , Paid a ...
(Date:5/4/2016)... According to market research "Global Computed ... to 2022 - Industry Insights by Slice Type (High, Mid ... by P&S Market Research, the global computed tomography market ... is expected to grow at a CAGR of 5.0% during ... is expected to witness the faster growth, CAGR of 5.3%, ...
Breaking Medicine Technology: